Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
Public ClinicalTrials.gov record NCT02135419. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer. The ANCHOR Data Safety Monitoring Board (DSMB) determined that the primary study endpoint was completed, based on the data and statistical analysis presented to them on 07SEP2021. In the post-randomization phase of this trial, all enrolled participants are offered treatment for HSIL and/or follow-up, at the participant's choice.
Study identification
- NCT ID
- NCT02135419
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 4,446 participants
Conditions and interventions
Conditions
Interventions
- imiquimod Drug
- fluorouracil Drug
- infrared photocoagulation therapy Device
- thermal ablation therapy Device
- laser therapy Device
- clinical observation Other
- laboratory biomarker analysis Other
Drug · Device · Other
Eligibility (public fields only)
- Age range
- 35 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 24, 2014 (Actual)
- Primary completion
- Aug 6, 2021 (Actual)
- Completion
- Mar 31, 2024 (Actual)
- Last update posted
- Jul 26, 2024
2014 – 2024
United States locations
- U.S. sites
- 24
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA CARE Clinic | Los Angeles | California | 90035 | — |
| UCLA School of Nursing | Los Angeles | California | 90095 | — |
| DAP Health | Palm Springs | California | 92262 | — |
| University of California at San Francisco Anal Dysplasia Clinic | San Francisco | California | 94115 | — |
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Denver Public Health | Denver | Colorado | 80204 | — |
| Capital Digestive Care | Washington D.C. | District of Columbia | 20006 | — |
| Dupont Circle Physicians Group | Washington D.C. | District of Columbia | 20009 | — |
| ACC Clinic, Jackson Hospital | Miami | Florida | 33136 | — |
| University of Miami Miller School of Medicine - Sylvester Cancer Center | Miami | Florida | 33136 | — |
| Grady Health System | Atlanta | Georgia | 30303 | — |
| Anal Dysplasia Clinic MidWest | Chicago | Illinois | 60614 | — |
| University Medical Center New Orleans | New Orleans | Louisiana | 70112 | — |
| CrescentCare Health | New Orleans | Louisiana | 70119 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Fenway Health | Boston | Massachusetts | 02215 | — |
| Rutgers University New Jersey Medical School | Newark | New Jersey | 07103 | — |
| Cornell Clinical Trials Unit, Chelsea Center | New York | New York | 10010 | — |
| Laser Surgery Care | New York | New York | 10011 | — |
| Montefiore - Albert Einstein College of Medicine | The Bronx | New York | 10461 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Harborview Medical Center | Seattle | Washington | 98104 | — |
| The Polyclinic | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02135419, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02135419 live on ClinicalTrials.gov.